UK-based contractor RSSL will set up an “innovation hub” it says will help small- and medium-sized biotech organization’s de-risk and accelerate the development of clinical candidates.
The aim – according to the firm – is to create an ecosystem for early-stage biotech's and small biopharmaceutical companies that provides access to laboratory space with a range of equipment and instrumentation available for use.
Jacinta George, managing director, RSSL said: “Our goal is to drive vital research and support innovation across the entire life science sector.
“We know how difficult it can be for emerging companies to access commercial facilities, so we're incredibly proud to be providing our support. Through this collaboration, we’re excited to help them develop the next wave of ground-breaking products — from life-changing cell and gene therapies to next-generation vaccines and medical devices.”
Companies that work with RSSL through the hub can access different levels of support, ranging from use of existing lab space through to a full-service option across the entire development pipeline, from initial concept to commercial manufacturing.
The hub will also offer a service – known as “forge” – that will provide companies with access to laboratory space, equipment, and services, plus consultancy in key areas such as training and regulatory compliance.
Expansion plan
RSSL framed the hub a key component of its long-term expansion strategy, adding that it plans to increase its operational capacity and breadth of services.
The firm cited the recent opening of an analytical testing facility on the University of Reading Whiteknights campus in the UK, which has added 26,000 square feet of working laboratory space.
At the time, RSSL said it was also planning to expand its workforce – currently around 350 employees - to over 500 in the next three years, adding that its aim is to double the number of scientists in its team.
DepositPhotos/ANDRANIK2017